Thursday, January 1, 2026 1/1/2026

Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections

Award Number: R01AI165915
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/10/2021
PERIOD OF PERFORMANCE END DATE: 10/31/2026

Group Awards By:

View Award Description

Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections - SUMMARY Urinary tract infections (UTIs) affect 15 million women in the United States every year and treatment for UTIs is becoming more difficult due to high rates of antibiotic resistance. Further, UTIs are highly recurrent. Between 20 and 40% of UTI episodes are followed by recurrent UTIs (rUTIs), with some women suffering as many as 6 or more recurrences per year. Uropathogenic Escherichia coli (UPEC) is the major causative agent of UTIs. Antibiotic resistance within UPEC isolates is rising, and the emergence of extended-spectrum beta-lactamase producing and fluoroquinolone resistant strains is a serious public health concern. Type 1 pili, tipped with the mannose binding FimH adhesin have been shown to be essential for bladder colonization and UTI pathogenesis in multiple mouse models. FimH mediates binding to mannosylated uroplakins lining the bladder surface to facilitate colonization and invasion into bladder cells where they rapidly replicate into intracellular bacterial communities that protect UPEC from immune cells and antibiotics. In addition, FimH facilitates the ability of UPEC to establish a reservoir in the GIT, from where they can seed UTIs by ascending from the periurethral area into the bladder. While UPEC are genetically variable, FimH is part of the core E. coli genome, although rare strains have been found with mutations in the type 1 operon. Immunization against FimH protects against UPEC UTI in murine and monkey cystitis models and a FimH-based vaccine has been allowed by the FDA for patients suffering from multi-drug resistant UPEC. In animal models, protection is antibody-mediated, as FimH- specific IgG antibodies are found in the urine from protected animals and can protect from UTI through passive transfer. Intriguingly, UPEC abundance in the gut is increased at the time of symptomatic UTI, suggesting that gut colonization is a key step in the rUTI cycle. Additionally, studies in this proposal show that eliciting a mucosal antibody response against FimH can reduce UPEC colonization of the gut. In light of these findings, this proposal addresses the hypothesis that anti-FimH induced antibodies can combat rUTI by two distinct mechanisms: i) prevention of UPEC binding to the uroepithelium; and ii) interference with UPEC colonization of the GIT, thereby lowering the likelihood of UPEC introduction into the urinary tract. The aims of this proposal are to: i) determine how mucosal vaccination against FimCH reduces UPEC gut colonization (Aim 1); ii) exploit vaccine induced B cell responses to isolate monoclonal antibodies (mAbs) to FimH and determine their epitope specificity (Aim 2); and iii) use these mAbs in mouse models of GIT colonization and cystitis in order to elucidate mechanisms of protection (Aim 3). The research plan will unravel the mechanisms by which anti-FimH antibodies may function to prevent UTIs by directly blocking bladder binding and indirectly by interfering with UPEC GIT colonization. These results will inform the rational targeting of the uropathogens that affect millions of people with rUTIs. In addition, our approach enables the rapid generation of anti-UPEC human mAbs that can be used for therapeutics and diagnostics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $622,331 )
2026	2026	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	5	12/2/2025	NON-COMPETING CONTINUATION	$622,331
														Subtotal = $622,331

Issue Date FY: 2025 ( Subtotal = $622,331 )
2025	2025	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	4	1/8/2025	NON-COMPETING CONTINUATION	$622,331
														Subtotal = $622,331

Issue Date FY: 2024 ( Subtotal = $622,331 )
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Allergy and Infectious Diseases Research	001	3	5/13/2024	NON-COMPETING CONTINUATION	$62,232
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	3	10/27/2023	NON-COMPETING CONTINUATION	$560,099
														Subtotal = $622,331

Issue Date FY: 2023 ( Subtotal = $627,667 )
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	2	10/14/2022	NON-COMPETING CONTINUATION	$627,667
														Subtotal = $627,667

Issue Date FY: 2022 ( Subtotal = $630,335 )
2022	2022	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Allergy and Infectious Diseases Research	000	1	11/9/2021	NEW	$630,335
														Subtotal = $630,335

Grand Total All Awards = $3,124,995

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections

Award Number: R01AI165915

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/10/2021

PERIOD OF PERFORMANCE END DATE: 10/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer